Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018, Article ID 2780272, 11 pages
https://doi.org/10.1155/2018/2780272
Clinical Study

Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients

1Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
3Ramathibodi Multidisciplinary Epilepsy Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
4The Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) Research Group, Bangkok, Thailand
5Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
6Department of Pharmacy, Prasat Neurological Institute, Bangkok, Thailand
7Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
8Department of Clinical Pharmacy Practice, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
9School of Medicine, Mae Fah Luang University, Chiang Rai, Thailand
10Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
11Division of Allergy and Clinical Immunology, Skin and Allergy Research Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
12Division of Dermatology, Skin and Allergy Research Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
13Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
14Dermatological Division, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
15Department of Community Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence should be addressed to Chonlaphat Sukasem; ht.ca.lodiham@kus.tahpalnohc

Received 17 August 2017; Revised 25 October 2017; Accepted 26 November 2017; Published 10 January 2018

Academic Editor: Riichiro Abe

Copyright © 2018 Chonlaphat Sukasem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. T. Illing, A. W. Purcell, and J. McCluskey, “The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions,” Immunogenetics, vol. 69, no. 8-9, pp. 617–630, 2017. View at Publisher · View at Google Scholar
  2. T. D. Fernandez, G. Canto, and M. Blanca, “Molecular mechanisms of maculopapular exanthema,” Current Opinion in Infectious Diseases, vol. 22, no. 3, pp. 272–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. I. Hung, W. H. Chung, S. H. Jee et al., “Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions,” Pharmacogenetics and Genomics, vol. 16, no. 4, pp. 297–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Z. Vern-Gross and A. Kowal-Vern, “Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review,” American Journal of Clinical Oncology, vol. 37, no. 5, pp. 506–513, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Thankachen and V. Agarwal, “Challenges in diagnosis, management, and treatment of allopurinol-induced DRESS syndrome: case report and literature review,” American Journal of Therapeutics, vol. 22, no. 3, pp. e77–e83, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. G. E. Besli, S. Yildirim, K. Yilmaz, and E. Yuksel, “DRESS syndrome or hematologic malignancy?: a case report of a 4-year-old boy,” Pediatric Emergency Care, vol. 33, no. 7, pp. 494–496, 2017. View at Publisher · View at Google Scholar
  7. H. M. Corneli, “DRESS syndrome: drug reaction with eosinophilia and systemic symptoms,” Pediatric Emergency Care, vol. 33, no. 7, pp. 499–502, 2017. View at Publisher · View at Google Scholar
  8. M. Shirzadi, A. Reimers, G. Helde, W. Sjursen, and E. Brodtkorb, “No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants 2(P24T) or 3(L48V) in Norwegian patients,” Seizure, vol. 45, pp. 169–171, 2017. View at Publisher · View at Google Scholar
  9. S. C. Su, S. I. Hung, W. L. Fan, R. L. Dao, and W. H. Chung, “Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation,” International Journal of Molecular Sciences, vol. 17, no. 11, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. W. H. Chung, C. W. Wang, and R. L. Dao, “Severe cutaneous adverse drug reactions,” The Journal of Dermatology, vol. 43, no. 7, pp. 758–766, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Dean, “Carbamazepine Therapy and HLA Genotypes,” in Medical Genetics Summaries, V. Pratt, H. McLeod, L. Dean, A. Malheiro, and W. Rubinstein, Eds., pp. 87–97, National Center for Biotechnology Information (US), Bethesda, MD, USA, 2012. View at Google Scholar
  12. W. H. Chung, S. I. Hung, H. S. Hong et al., “Medical genetics: a marker for Stevens–Johnson syndrome,” Nature, vol. 428, no. 6982, p. 486, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. G. Leckband, J. R. Kelsoe, H. M. Dunnenberger et al., “Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing,” Clinical Pharmacology and Therapeutics, vol. 94, no. 3, pp. 324–328, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. P. B. Ferrell Jr. and H. L. McLeod, “Carbamazepine, HLA-B1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations,” Pharmacogenomics, vol. 9, no. 10, pp. 1543–1546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Tangamornsuksan, N. Chaiyakunapruk, R. Somkrua, M. Lohitnavy, and W. Tassaneeyakul, “Relationship between the HLA-B1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis,” JAMA Dermatology, vol. 149, no. 9, pp. 1025–1032, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Grover and R. Kukreti, “HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis,” Pharmacogenetics and Genomics, vol. 24, no. 2, pp. 94–112, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. McCormack, A. Alfirevic, S. Bourgeois et al., “HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans,” The New England Journal of Medicine, vol. 364, no. 12, pp. 1134–1143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Genin, D. P. Chen, S. I. Hung et al., “HLA-A31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis,” The Pharmacogenomics Journal, vol. 14, no. 3, pp. 281–288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. H. Hsiao, R. C. Y. Hui, T. Wu et al., “Genotype–phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations,” Journal of Dermatological Science, vol. 73, no. 2, pp. 101–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Tassaneeyakul, S. Tiamkao, T. Jantararoungtong et al., “Association between HLA-B1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population,” Epilepsia, vol. 51, no. 5, pp. 926–930, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Jaruthamsophon, V. Tipmanee, A. Sangiemchoey, C. Sukasem, and P. Limprasert, “HLA-B15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis,” Scientific Reports, vol. 7, article 45553, 2017. View at Publisher · View at Google Scholar
  22. C. Sukasem, T. Jantararoungtong, P. Kuntawong et al., “HLA-B58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand,” Frontiers in Pharmacology, vol. 7, p. 186, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. W. Shi, F. L. Min, D. Zhou et al., “HLA-A24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions,” Neurology, vol. 88, no. 23, pp. 2183–2191, 2017. View at Publisher · View at Google Scholar
  24. Y. C. Chen, Y. T. Cho, C. Y. Chang, and C. Y. Chu, “Drug reaction with eosinophilia and systemic symptoms: a drug-induced hypersensitivity syndrome with variable clinical features,” Dermatologica Sinica, vol. 31, no. 4, pp. 196–204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Kaniwa and Y. Saito, “Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury,” Journal of Human Genetics, vol. 58, no. 6, pp. 317–326, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Ozeki, T. Mushiroda, A. Yowang et al., “Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population,” Human Molecular Genetics, vol. 20, no. 5, pp. 1034–1041, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Locharernkul, J. Loplumlert, C. Limotai et al., “Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B1502 allele in Thai population,” Epilepsia, vol. 49, no. 12, pp. 2087–2091, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Kulkantrakorn, W. Tassaneeyakul, S. Tiamkao et al., “HLA-B1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain,” Pain Practice, vol. 12, no. 3, pp. 202–208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Puangpetch, N. Koomdee, M. Chamnanphol et al., “HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity,” Frontiers in Genetics, vol. 5, p. 478, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. K. Cheung, S. H. Cheng, E. J. M. Chan, S. V. Lo, M. H. L. Ng, and P. Kwan, “HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese,” Epilepsia, vol. 54, no. 7, pp. 1307–1314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. Q. Wang, S. Sun, M. Xie, K. Zhao, X. Li, and Z. Zhao, “Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a meta-analysis,” Epilepsy Research, vol. 135, pp. 19–28, 2017. View at Publisher · View at Google Scholar
  32. N. Saksit, W. Tassaneeyakul, N. Nakkam et al., “Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population,” Pharmacogenetics and Genomics, vol. 27, no. 7, pp. 255–263, 2017. View at Publisher · View at Google Scholar
  33. M. Pirmohamed, D. A. Ostrov, and B. K. Park, “New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity,” The Journal of Allergy and Clinical Immunology, vol. 136, no. 2, pp. 236–244, 2015. View at Publisher · View at Google Scholar · View at Scopus